Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Double-dummy, Active Drug Parallel-controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of Oral HPP737 in Adult Patients With Moderate to Severe Plaque Psoriasis.

NCT07712731 is registered in ClinicalTrials.gov with Newsoara Biopharma Co., Ltd. as lead sponsor.

NCT NCT07712731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07712731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Double-dummy, Active Drug Parallel-controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of Oral HPP737 in Adult Patients With Moderate to Severe Plaque Psoriasis.
Lead sponsor
Newsoara Biopharma Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
April 18, 2025
Completion date
April 1, 2026
Enrollment
607 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis